Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016-2021.

Wang X, Dormont F, Lorenzato C, Latouche A, Hernandez R, Rouzier R

Open source

DOI
10.1016/j.jcpo.2023.100403
Published
2023 Mar
Container
Journal of cancer policy
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jcpo.2023.100403,
  title = {Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016-2021.},
  author = {Wang X and Dormont F and Lorenzato C and Latouche A and Hernandez R and Rouzier R},
  year = {2023},
  journal = {Journal of cancer policy},
  doi = {10.1016/j.jcpo.2023.100403},
  url = {https://doi.org/10.1016/j.jcpo.2023.100403}
}

RIS

TY  - JOUR
TI  - Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016-2021.
AU  - Wang X
AU  - Dormont F
AU  - Lorenzato C
AU  - Latouche A
AU  - Hernandez R
AU  - Rouzier R
PY  - 2023
JO  - Journal of cancer policy
DO  - 10.1016/j.jcpo.2023.100403
UR  - https://doi.org/10.1016/j.jcpo.2023.100403
ER  - 

APA

X, W., F, D., C, L., A, L., R, H., & R, R. (2023). Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016-2021.. Journal of cancer policy. https://doi.org/10.1016/j.jcpo.2023.100403

Source records